Atezolizumab, a PD-L1 Inhibitor: An Association of Bleeding Gastric Ulcer With Its Use

Atezolizumab is a programmed death-ligand 1 inhibitor, an immune checkpoint inhibitor (ICI), useful in various advanced solid malignancies. As atezolizumab is more commonly used nowadays, physicians should be aware of the rare associated adverse events (AEs). Most of the AEs associated with the ICIs...

Descripción completa

Detalles Bibliográficos
Autores principales: Bapatla, Anusha, Tariq, Tooba, Haider, Maryam Bilal, Mohamad, Bashar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208334/
https://www.ncbi.nlm.nih.gov/pubmed/34150414
http://dx.doi.org/10.7759/cureus.15637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208334/
https://www.ncbi.nlm.nih.gov/pubmed/34150414
http://dx.doi.org/10.7759/cureus.15637

Ejemplares similares